London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
UK respiratory disease specialist Verona Pharma (Nasdaq: VRNA) and its wholly-owned subsidiary, Verona Pharma Inc (VPI) have entered into strategic financing agreements securing access to up to $650 million from funds managed by Oaktree Capital Management and OMERS Life Sciences, adding to a $400 million debt facility with Oxford Finance and Hercules Capital deal in January this year.
The new agreements provide non-dilutive capital and additional financial…
Not sure why you've posted this Tommy ? You do know why the funding - which was propossed by Oaktree and not sought by the company - has been agreed ?
I mean it's great that you are shining a light on another company's very good drug and I salute your continued classy focus on the entirety of the marketplace SNG will one day hope to be selling into. And at the same time thinking of the poor sufferers who will soon find relief. It all does you tremendous credit.
Verona's Ensifentrine - for this is the drug - will benefit greatly from the developmental funds released in this deal - as it awaits almost certain NDA on June 26th. They are discussing their 36% P3 efficacy at ATS so maybe PM can share his specialist knowledge with them, show them his poster and buy them all a beer. While he's at it he can look up Sanofi/Regeneron's Dupilumab team and shout them a stubby too. They presented their 34% P3 data today and are also waiting for a likely sBLA which is expected a day later on June 27th. All pals together in the COPDosphere I'm sure - and plenty of the huge COPD pie to go round.
Tremendous really & I agree with you - 2 fantastic new and complimentary drugs almost ready to bring relief to a wheezing spluttering world.
This is a good read for COPD watchers. " COPD Market poised for paradigm shift "
https://www.biospace.com/article/copd-market-poised-for-paradigm-shift-with-potential-approvals-in-2024-globaldata/#:~:text=Potential%20FDA%20approvals%20this%20year,report%20from%20analytics%20firm%20GlobalData.
Poor Doc D so desperate from his basement not to acknowledge non dilutive funding exists in the Pharma world for promising drugs.
I wonder why?
You sound increasingly bitter DocDan, worried that the company might one day succeed?
Sure Tommy - you're always posting about competitors with stellar COPD data. Thanks again for the heads up. Really pleased for Verona, Sanofi and Regeneron. Companies with modern tailor-made drugs that offer long term solutions - even using inhalation as a delivery mechanism ( just imagine !!) - for COPD and most likely every other RVI out there.
Fruits - yes I have become disillusioned and even occasionally bitter when you two are posting your fanboy nonsense. My eyes are wide open and I've finally lost faith in this company - even as it stands on the threshold. I know nothing of what they've been doing over the last year and UNIVERSAL's results are utterly predictable and of no use whatsoever. The company will announce protocols for the P2s with almost exactly the inclusion criteria of the failed Home trial. Age and Comorbidities. Imagine that. They will run a trial or trials that they could have started 2 years ago and with protocols that should have informed the Sprinter trial. Nothing new or ground breaking - none of the tailor made space age diagnostics we were promised - and that Tommy said the drug had been waiting 25 years for - and whatever equity we have left will be surrendered in just getting past the P2s. Even if Casanolabs has done something clever it still needs to be turned into a fast test which if they're lucky will help to deliver an extra 10% of patients who may or may not benefit from SNG. They will go with age and comorbidities and run predictable little trials with predictable results. An improvement in LOS is the best hope. They may have success in incubated patients I guess - if the regulators let them in to the HDU. Then - when the money's gone - some other company will finally get it over the line and one day we'll be able to applaud another AZ success story.
"UNIVERSAL's results are utterly predictable and of no use whatsoever."
I feel you are not well suited to this type of investment. You judge well before you learn the meaning of the significance of things, constantly 2nd guessing worst case scenarios only to then end up disappointed, which feels rather an intentional MO than a true shortcoming..... That level of ignorance will only lead to disillusionment, you are right. Confucius say maybe time to sell you shares as you see no further upturn here. Why hang on to them? It's not like you believe in the drug or the company's prospects. Maybe invest in Verona, Sanofi and Regeneron. As you say; "Companies with modern tailor-made drugs that offer long term solutions - even using inhalation as a delivery mechanism ( just imagine !!) - for COPD and most likely every other RVI out there".
Oh, little Bobby Axelrod is back with pictures of sunrises?
lol